Results 61 to 70 of about 9,857 (174)

A Four‐Center Study on the Activity of Aztreonam and Aztreonam‐Avibactam Combination Against Clinical Isolates of Gram‐Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β‐Lactamases

open access: yesAPMIS, Volume 134, Issue 9, September 2026.
ABSTRACT We aimed to investigate the activity of aztreonam and aztreonam‐avibactam combination against gram‐negative bacilli producing different types of β‐lactamases. Activity of aztreonam and aztreonam‐avibactam against 166 isolates (33 AmpC‐producing, 33 ESBL‐producing, 66 carbapenemase‐producing Enterobacterales, 34 metallo‐β‐lactamase‐producing P.
Gizem İnce Ceviz   +7 more
wiley   +1 more source

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

open access: yesФармакоэкономика, 2019
Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods.
S. V. Nedogoda   +3 more
doaj   +1 more source

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

open access: yesBrazilian Journal of Infectious Diseases, 2021
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky   +8 more
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

open access: yesTransplant Infectious Disease, Volume 28, Issue 5, September/October 2026.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti   +6 more
wiley   +1 more source

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient

open access: yesIDCases, 2019
Ceftazidime–avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill ...
Maria Vargas   +4 more
doaj   +1 more source

In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

open access: yesJournal of Global Antimicrobial Resistance, 2020
Objectives: The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood ...
Chiara Papalini   +6 more
doaj   +1 more source

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

open access: yesFrontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang   +4 more
doaj   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari   +2 more
wiley   +1 more source

Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline

open access: yesIDCases, 2020
Ceftazidime/avibactam combines ceftazidime with a new beta-lactam that successfully that inhibits Amber Class A and D carbapenemases.We report a clinical case of a 61 year-old man with a carbapenemase-producing Klebsiella pneumoniae intra-abdominal ...
Mariana Guedes   +4 more
doaj   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

open access: yesInternational Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy